Hematopoietic Stem Cell Transplantation Market Landscape to Evolve at a CAGR of 12.4% During the Forecast Period (2026-2036) as Novel Therapies and Expanding Patient Eligibility Drive Growth | DelveInsight

The hematopoietic stem cell transplantation market is experiencing steady growth, driven by the rising prevalence of hematologic malignancies, advances in transplant techniques, donor matching technologies, and supportive care have significantly improved transplant outcomes, expanding the eligible patient population. Additionally, the expected launch of emerging therapies such as OTL-203 (Orchard Therapeutics), Orca-T (Orca Biosystems), Iomab-B (I-131 apamistamab) (Actinium Pharmaceuticals), and others will further fuel the market growth.

LAS VEGAS, June 22, 2026 /PRNewswire/ -- Recently published Hematopoietic Stem Cell Transplantation Market Insights report includes a comprehensive understanding of current treatment practices, hematopoietic stem cell transplantation emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Hematopoietic Stem Cell Transplantation Market Summary

• The total market size of hematopoietic stem cell transplantation treatment in the 7MM in 2025 was approximately USD 910 million.
• The US hematopoietic stem cell transplantation market accounted for the largest market share in 2025, i.e., 61% as compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan hematopoietic stem cell transplantation market.
• The total number of HSCT procedures in the 7MM was around 55,000 cases in 2025, reflecting a substantial clinical burden and the growing reliance on advanced transplant approaches for managing complex hematologic conditions across major markets.
• Leading hematopoietic stem cell transplantation companies, such as Orchard Therapeutics, Orca Biosystems, Actinium Pharmaceuticals, MaaT Pharma, Bristol-Myers Squibb, Regimmune, and others, are developing new hematopoietic stem cell transplantation treatment drugs that can be available in the hematopoietic stem cell transplantation market in the coming years. 
• The promising hematopoietic stem cell transplantation therapies in clinical trials include OTL-203, Orca-T, Iomab-B (I-131 apamistamab), MaaT033, Iberdomide, RGI-2001, and others.
• In 2036, Orca-T is projected to generate the highest revenue among emerging HSCT therapies in the 7MM.

Discover the hematopoietic stem cell transplantation market share by 2036 @ https://www.delveinsight.com/report-store/hematopoietic-stem-cell-transplantation-market

Key Factors Driving the Growth of the Hematopoietic Stem Cell Transplantation Market 

• Increasing Prevalence of Hematologic Disorders: The rising incidence of leukemia, lymphoma, multiple myeloma, aplastic anemia, and inherited blood disorders is driving demand for HSCT as a potentially curative treatment option.
• Expansion of HSCT Indications: Growing clinical evidence supporting HSCT in both malignant and non-malignant diseases has broadened its application, increasing the number of eligible patients worldwide.
• Advancements in Transplant Technologies: Innovations in stem cell sourcing, graft engineering, conditioning regimens, and supportive care have improved transplant outcomes and reduced procedure-related complications.
• Growing Adoption of Alternative Donor Transplants: The increasing use of haploidentical, matched-unrelated, and cord blood transplants has expanded donor availability, enabling more patients to undergo HSCT.
• Expected Launch of Emerging HSCT Drugs: The dynamics of the HSCT market are expected to change in the coming years due to the launch of emerging therapies such as OTL-203 (Orchard Therapeutics), Orca-T (Orca Biosystems), Iomab-B (I-131 apamistamab) (Actinium Pharmaceuticals), MaaT033 (MaaT Pharma), Iberdomide (Bristol-Myers Squibb), RGI-2001 (Regimmune), and others.

Ramandeep Singh, Senior Consultant of Forecasting at DelveInsight, said that the integration with next-generation cellular and immune therapies, such as CAR T cells and post-transplant maintenance strategies, creates potential for synergistic or sequential treatment paradigms.

Hematopoietic Stem Cell Transplantation Market Analysis

• Current hematopoietic stem cell transplantation strategies primarily depend on conditioning regimens and supportive pharmacological therapies. 
• Key approved products in this space include Treosulfan, Omidubicel-onlv, Exagamglogene autotemcel, UM171-expanded CD34+ dorocubicel, Motixafortide, MABCAMPATH, and THYMOGLOBULIN. 
• However, despite these advancements, issues such as graft failure and transplant-associated complications continue to limit long-term outcomes, highlighting the need for more effective and durable HSCT innovations.
• A new generation of investigational therapies, including OTL-203, Orca-T, Iomab-B, and MaaT033, is transforming the HSCT landscape. By incorporating advanced conditioning strategies, engineered cellular products, and microbiome-focused interventions, these emerging therapies have the potential to broaden treatment options and further advance the field of transplantation.
• Nevertheless, substantial unmet needs remain. Disease relapse continues to be the leading cause of death among patients with high-risk malignancies, often linked to measurable residual disease (MRD) before transplantation and mechanisms of immune evasion. 
• In addition, both acute and chronic graft-versus-host disease remain major contributors to long-term morbidity, frequently necessitating extended immunosuppressive therapy because of the absence of well-established maintenance approaches. 
• Consequently, there is a pressing need for novel therapies capable of sustaining long-term remission while effectively reducing the risk of steroid-refractory and other severe transplant-related complications.

Hematopoietic Stem Cell Transplantation Competitive Landscape

Some of the HSCT drugs under development include OTL-203 (Orchard Therapeutics), Orca-T (Orca Biosystems), Iomab-B (I-131 apamistamab) (Actinium Pharmaceuticals), MaaT033 (MaaT Pharma), Iberdomide (Bristol-Myers Squibb), RGI-2001 (Regimmune), and others.

Orchard Therapeutics' OTL-203 is a Phase III investigational ex vivo autologous hematopoietic stem cell transplantation (HSCT)-based gene therapy being developed for the treatment of mucopolysaccharidosis type I Hurler syndrome (MPS-IH). Administered as a one-time treatment, it is designed to provide long-term enzyme expression throughout the body and central nervous system, to address both physical and neurocognitive disease manifestations while potentially overcoming the challenges associated with allogeneic HSCT.

Orca Bio's Orca-T is an investigational allogeneic T-cell immunotherapy being studied for the treatment of various hematologic malignancies, including acute leukemias and myelodysplastic syndromes. The therapy consists of highly purified hematopoietic stem cells, regulatory T cells, and conventional T cells sourced from matched related or unrelated donors. The U.S. FDA has granted Orca-T both Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Drug designation for reducing the risk of graft-versus-host disease (GVHD) or death in patients undergoing hematopoietic stem cell transplantation.

Actinium Pharmaceuticals' Iomab-B is a first-in-class targeted radiotherapeutic agent developed to expand access to potentially curative bone marrow transplantation (BMT). By selectively eliminating CD45-expressing blood cancer cells, immune cells, and bone marrow stem cells, it aims to facilitate successful transplantation while minimizing treatment-related toxicity. Clinical studies involving more than 400 patients have demonstrated its ability to improve access to BMT, enhance survival outcomes, and maintain tolerability. These findings include results from the Phase III SIERRA trial evaluating patients aged 55 years and older with active, relapsed, or refractory acute myeloid leukemia (AML).

The anticipated launch of these emerging therapies are poised to transform the hematopoietic stem cell transplantation market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the hematopoietic stem cell transplantation market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the hematopoietic stem cell transplantation (HSCT) market @ Hematopoietic Stem Cell Transplantation Market Analysis

Recent Developments in the Hematopoietic Stem Cell Transplantation Market

• In April 2026, Orca Bio announced that the FDA had prolonged the review period for its Biologics License Application (BLA) seeking approval of Orca-T for patients with hematologic malignancies. The revised Prescription Drug User Fee Act (PDUFA) action date has been set for July 6, 2026.
• In December 2025, the FDA approved OMISIRGE for a second indication in Severe Aplastic Anemia, making it the first cellular therapy licensed for this condition and expanding use to patients aged 6 years and older following reduced intensity conditioning when a compatible donor is not available.

What is Hematopoietic Stem Cell Transplantation?

Hematopoietic stem cell transplantation (HSCT), also known as a bone marrow or stem cell transplant, is a medical procedure used to replace damaged, diseased, or dysfunctional blood-forming stem cells with healthy hematopoietic stem cells. These stem cells, obtained from the bone marrow, peripheral blood, or umbilical cord blood of the patient or a donor, can regenerate the entire blood and immune system. HSCT is widely used in the treatment of various hematologic malignancies, including leukemia, lymphoma, and multiple myeloma, as well as certain inherited blood disorders, immune deficiencies, and autoimmune diseases. The procedure typically involves high-dose chemotherapy and/or radiation therapy to eliminate diseased cells before the infusion of healthy stem cells, which subsequently engraft in the bone marrow and restore normal blood cell production and immune function. HSCT has become a cornerstone of curative therapy for many life-threatening hematological conditions, significantly improving patient survival and long-term outcomes.

Hematopoietic Stem Cell Transplantation Epidemiology Segmentation

The hematopoietic stem cell transplantation epidemiology section provides insights into the historical and current hematopoietic stem cell transplantation patient pool and forecasted trends for the leading markets. In 2025, in EU4 and the UK, HSCT procedures were categorized by transplant type, with autologous HSCT accounting for 15,000 cases and allogeneic HSCT comprising 11,500 cases, highlighting the utilization of both transplant approaches across the region.

The hematopoietic stem cell transplantation treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Hematopoietic Stem Cell Transplantation (HSCT) Cases
• HSCT Cases by Indication
• HSCT Cases by Type
• HSCT Cases by Age
• HSCT Cases by Source 

Scope of the Hematopoietic Stem Cell Transplantation Market Report

• Hematopoietic Stem Cell Transplantation Patient Population Forecast
• Hematopoietic Stem Cell Transplantation Therapeutics Market Size
• Hematopoietic Stem Cell Transplantation Pipeline Analysis
• Hematopoietic Stem Cell Transplantation Market Size and Trends
• Hematopoietic Stem Cell Transplantation Market Opportunity
• Hematopoietic Stem Cell Transplantation Market Unmet Needs
• KOL's Views on Hematopoietic Stem Cell Transplantation
• Hematopoietic Stem Cell Transplantation Market Access and Reimbursement

Download the report to understand what cells are used for hematopoietic stem cell transplantation @ Hematopoietic Stem Cell Transplantation Market Trends

Table of Contents

Related Reports

Hematopoietic Stem Cell Transplantation Clinical Trial Analysis

Hematopoietic Stem Cell Transplantation Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HSCT companies, including Actinium Pharmaceuticals, BioLineRx, Athersys, Novartis, CareDex, Orchard Therapeutics, Magenta Therapeutics, Graphite Bio, Vor Biopharma, Jasper Therapeutics, Garuda Therapeutics, and others.

Allogeneic Hematopoietic Stem Cell Transplantation Market

Allogeneic Hematopoietic Stem Cell Transplantation Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Allo-HSCT companies, including Novartis, Takeda, Gilead Sciences, Lonza, Amgen, and others.

Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key AML companies, including Daiichi Sankyo, Agios Pharma, Astellas Pharma, Rigel Pharmaceuticals, Jazz Pharmaceuticals, Novartis, Pfizer, Abbvie, BMS, Arog Pharmaceuticals, Actinium Pharmaceutical, Astex Pharmaceutical, Syndax, Geron, SELLAS Life Sciences, Johnson & Johnson Innovative Medicine, Sanofi, Affimed, Sumitomo Pharma, Kura Oncology, CULLINAN THERAPEUTICS, Molecular Partners, Caribou Biosciences, BioPath Holdings, and others.

Graft versus Host Disease Market

Graft versus Host Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GvHD companies, including CSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech (Yifan Pharmaceutical), Ironwood, medac, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg